HemostOD secures a CHF 4.3M seed extension round

The round was co-led by Polytech Ventures and Orenok Holdings, with additional participation from the Lichtsteiner Foundation and other private investors.

Funding Details: - Total Amount: CHF 4.3M - Lead Investors: Polytech Ventures and Orenok Holdings - Additional Participants: Lichtsteiner Foundation and other private investors

Use of Funds: This significant funding will enable HemostOD to: - Advance through pre-IND (Investigational New Drug) development - Scale up commercial production capabilities - Accelerate clinical development programs - Strengthen our manufacturing platform for universal platelets

Company Milestones: With this funding, HemostOD continues to build on its innovative platelet manufacturing technology, moving closer to bringing universal platelets to patients in need. The company's proprietary platform addresses the global shortage of platelet transfusions through scalable, engineered platelet production.

About HemostOD: HemostOD is a Swiss preclinical biotech company developing universal platelets for transfusion medicine. Our innovative platform enables the production of engineered platelets from immortalized hematopoietic stem cells, providing a scalable solution to address platelet shortages worldwide.

For more information about this funding round and HemostOD's technology platform, please contact our team.